Sentynl Therapeutics licenses Progerinin for Hutchinson-Gilford Progeria Syndrome treatment

Key facts

• Sentynl Therapeutics Inc. (Sentynl), a wholly-owned subsidiary of Zydus Lifesciences Limited (Zydus), has entered into an agreement with Korean company PRG S&T to license the investigational molecule Progerinin (SLC-D011).
• Progerinin (SLC-D011) is an orally active small-molecule drug candidate being developed to treat Hutchinson-Gilford Progeria Syndrome (HGPS), a rare genetic disorder characterised by accelerated ageing in children.
• The United States Food and Drug Administration (FDA) has designated Progerinin (SLC-D011) as an orphan drug.
• The molecule is designed to inhibit the interaction of progerin, an abnormal form of the lamin A protein produced by mutations in the LMNA gene that disrupts nuclear structure.
• The clinical programme is currently finalising a Phase 2A trial, with data results expected before the end of the first half of 2026.
• Currently, Zokinvy (lonafarnib) is the only approved treatment for HGPS and certain processing-deficient Progeroid Laminopathies in the United States, European Union, Great Britain, Israel, and Japan.
• In mouse models of HGPS, Progerinin demonstrated an increase in lifespan by 8 to 10 weeks and improved body weight compared to untreated control groups.